Anti Collagen 4 (ALPHA)5(IV) mAb (Clone B51, Fluorescein Labeled)

Cosmo Bio LTD

Catalog No: SGE-CFT451

Click here to browse a well organized list of products for Bone, Collagen, and Extracellular Matrix research.

Check out our Human Collagen IVα Rat Monoclonal Antibodies Dashboard for more information about this product and additional epitope-defined monoclonal antibodies useful for research on hereditary diseases related to collagen IV, including our popular Anti-Collagen 4 Cocktail mAb (Clones H53, B51, H25) (SGE-CFT45325).

---

Alport syndrome is an inherited disease characterized by the pathological absence or reduction of the collagen α5(IV) chain in glomerular basement membrane (GBM), tubular basement membrane (TBM) and Bowman's capsular basement membrane. Anti Collagen 4 (ALPHA)5(IV) mAb (Clone B51, Fluorescein Labeled) (cat no. SGE-CFT451) is one of three different rat mAbs included in Anti-Collagen 4 Cocktail mAb (Clones H53, B51, H25) (SGE-CFT45325) for easy and rapid staining of human renal and skin biopsy sections to distinguish Alport syndrome from normal tissue. Anti-Collagen 4 Cocktail mAb (Clones H53, B51, H25) comprises two different FITC-conjugated mAbs (clones H53 and B51) that reveal the Alport-affected α5(IV) chain in glomerular, tubular and Bowman's capsular BMs and an internal positive control Texas Red-conjugated mAb (clone H25) that targets α2(IV) to reveal endothelial basement membrane structure

---

Product specifications

Specification	Detail
Anti Collagen 4 (ALPHA)5(IV) mAb (Clone B51, Fluorescein Labeled)
Cat No	SGE-CFT451
Application	Staining of human cryostat sections by direct immunofluorescence (acid-urea treatment not required)
Quantity	0.5 ml
Appearance	Solution, 0.1% NaN3 as preservative
Purification	Affinity chromatography
Fluorescent labeling	FITC
Clone name	B51 (rat IgG2a)
Specificity	B51 is specific to the NC1 domain of human α5(IV). Not reactive with human α1, α2, α3, α4 and α6). The amino acid sequence of the epitope is IDVEF. (Reference 1).
Antibodies preparation	Monoclonal antibody was prepared by the rat lymph node method developed by Shigei Medical Research Institute with a synthetic peptide of type IV collagen as immunogen.
Storage	In the dark at 2-4°C. Stable for 2 years under this condition.
Source	Shigei Medical Research Institute, 2117 Yamada, Okayama 701-0202, Japan; TEL: +81-86-282-3113; FAX: +81-86-282-3115; E-mail: inst@shigei.or.jp

---

References

1. Kagawa M et al.
   Epitope-defined monoclonal antibodies against type-IV collagen for diagnosis of Alport syndrome.
   Nephrol. Dial. Transplant. 12: 1238-1241 (1997) (PMID: 9198058)
2. Borza DB et al.
   The NCI domain of collagen IV encodes a novel network composed of the α1, α2, α5, and α6 chains in smooth muscle basement membranes.
   J. Biol. Chem. 276: 28532-28540 (2001) (PMID: 11375996)
3. Sado et al.
   Establishment by the rat lymph node method of epitope-defined monoclonal antibodies recognizing the six different α chains of human type IV collagen.
   Histochem. Cell Biol. 104: 267-275 (1995) (PMID: 8548560)
4. Yoshioka K et al.
   Type IV collagen α5 chain: Normal distribution and abnormalities in X-linked Alport syndrome revealed by monoclonal antibody.
   Am. J. Pathol. 144: 986-996 (1994) (PMID: 8178947)
5. Ninomiya Y et al.
   Differential expression of two basement membrane collagen genes, COL4A6 and COL4A5, demonstrated by immunofluorescence staining using peptide-specific monoclonal antibodies.
   J. Cell Biol. 130: 1219-1229 (1995) (PMID: 7657706)
6. Naito I et al.
   Relationship between COL4A5 gene mutation and distribution of type IV collagen in male X-linked Alport syndrome.
   Kidney Int. 50: 304-311 (1996) (PMID: 8807602)

---

Citations

1. Bu L et al.
   Somatic Mosaicism in a Male Patient With X-linked Alport Syndrome.
   Kidney Int Rep. 14(4): 1031-1035 (2019) (PMID: 31312776)
2. Samar M et al.
   Negative Staining for COL4A5 Correlates With Worse Prognosis and More Severe Ultrastructural Alterations in Males With Alport Syndrome.
   Kidney Int Rep. 2(1): 44-52 (2017) (PMID: 29142939)
3. Malone AF et al.
   Functional assessment of a novel COL4A5 splice region variant and immunostaining of plucked hair follicles as an alternative method of diagnosis in X-linked Alport syndrome.
   Pediatr Nephrol. 32(6): 997-1003 (2017) (PMID: 28013382)
4. Nozu K et al.
   X-linked Alport syndrome caused by splicing mutations in COL4A5.
   Am Soc Nephrol. 9(11): 1958-64 (2014) (PMID: 25183659)
5. Matsubara S et al.
   Pregnancy complicated with Alport syndrome: a good obstetric outcome and failure to diagnose an infant born to a mother with Alport syndrome by umbilical cord immunofluorescence staining.
   Obstet Gynaecol Res. 35(6): 1109-14 (2009) (PMID: 20144175)
6. Patey-Mariaud de Serre N et al.
   Collagen alpha5 and alpha2(IV) chain coexpression: analysis of skin biopsies of Alport patients.
   Kidney Int. 72(4): 512-6 (2007) (PMID: 17554254)
7. Kharrat M et al.
   Autosomal dominant Alport's syndrome: study of a large Tunisian family.
   Kidney Dis Transpl. 17(3): 320-5 (2006) (PMID: 16970251)